64Cu-DOTA-nivolumab (Bristol-Myers Squibb/Ono Pharmaceutical)

N/A

Report date: 2023/02/26 21:49:43

Base Information

Drug Name64Cu-DOTA-nivolumab (Bristol-Myers Squibb/Ono Pharmaceutical)
Drug Alias Namenivolumab-[64Cu]-DOTA
ClassificationBiologics
Mechanisms of ActionPositron-emission tomography enhancers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesOno Pharmaceutical Co LtdBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb CompanyOno Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A